Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-03-22
2011-03-22
Harris, Alana M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S380000, C530S386000, C530S387100, C530S387700, C530S388100, C530S388150
Reexamination Certificate
active
07910704
ABSTRACT:
Novel human p53 splice variant displaying differential transcriptional activity Described is a nucleic acid molecule encoding a p53 variant characterized in that it is capable of transactivating the p21- and 14-3-3σ-promoter but not the mdm2-, bax- and PIG3-promoter. Preferably, in said p53 variant exon 7, exon 8 and/or exon 9 are partially or entirely deleted. Finally, means for inhibiting the activity of this p53 variant are described which are useful for the therapy of cancer.
REFERENCES:
patent: 6307036 (2001-10-01), Milner et al.
patent: WO 00/22127 (2000-04-01), None
Harlow and Lane. Antibodies, A Laboratory Manual, pp. 319-325 and 340-352, 1988.
Gannon et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. The EMBO Journal 9(5): 1595-1602, 1990.
Campomenosi, Paola, et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements,Oncogene(2001) 20, pp. 3573-3579.
Dell' Acqua, G., et al.p35: identification, characterization and functional studies of a novel p53 alternative splice product in the rat, Brigham and Women's Hospital, Harvard Medical School (1999) p. 852.
El-Deiry, W.S. The p53 pathway and cancer therapy,The Cancer Journal(1998) 11, No. 5, pp. 229-236.
Fukuda I., et al., Alternatively-Spliced p53 mRNA in the FAA-HTC1 Rat Hepatoma Cell Line without the Splice Site Mutations,Cell Structure and Fusion(1992) 17, pp. 427-432.
Hermeking, Heiko, et al. 14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression,Molecular Cell(1997) 1, pp. 3-11.
Nakai, Hiroyuki, et al. Multiple aberrant splicing of the p53 transcript without genomic mutations around exon-intron junctions in a case of chronic myelogenous leukaemia in blast crisis: a possible novel mechanism of p53 inactivation,British Journal of Haematology(1994) 87, pp. 839-842.
Ruggeri, Bruce A., et al. Molecular Pathology of Primary and Metastatic Ductal Pancreatic Lesions,American Cancer Society(1997) 79, No. 4, pp. 700-716.
Deppert Wolfgang W.
Dornreiter Irene
Harris Alana M.
Lerner David Littenberg Krumholz & Mentlik LLP
LandOfFree
Human p53 splice variant displaying differential... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human p53 splice variant displaying differential..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human p53 splice variant displaying differential... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2735879